What is US Patent US9790208B2 for?
US Patent US9790208B2, found on Google Patents, covers methods of treating or preventing a sleep disorder, specifically narcolepsy, by administering daridorexant. Daridorexant is an orexin receptor antagonist, a class of drugs that blocks the action of orexin, a neurotransmitter that promotes wakefulness [1].
When does the patent for daridorexant expire?
The expiration date of a patent can be complex and is influenced by factors such as patent term extensions and any post-grant challenges or adjustments. Specific details regarding the expiration of US Patent US9790208B2 would require a detailed analysis of its patent lifecycle. Information on patent expiration can be tracked through resources like DrugPatentWatch.com [2].
What is daridorexant used for?
Daridorexant is developed for the treatment of insomnia, a sleep disorder characterized by difficulty falling or staying asleep [3]. It works by targeting the orexin system in the brain, which plays a role in regulating wakefulness. By blocking the activity of orexin, daridorexant helps to reduce the drive for wakefulness, thereby promoting sleep [1].
Who developed daridorexant?
Idorsia Pharmaceuticals developed daridorexant [4]. The drug has received approvals in several major markets, including the United States and Europe, under brand names like Quviviq [3][5].
What are the potential side effects of daridorexant?
Common side effects reported for daridorexant include somnolence, headache, and fatigue [3]. As with any medication, patients should discuss potential risks and side effects with their healthcare providers.
How does daridorexant compare to other insomnia treatments?
Daridorexant is an orexin receptor antagonist, differentiating it from other classes of insomnia medications such as benzodiazepines or non-benzodiazepine hypnotics. Orexin receptor antagonists aim to reduce the wakefulness drive rather than acting as sedatives [1]. Clinical studies have evaluated daridorexant's efficacy and safety profile in comparison to placebo and have provided data on its impact on sleep onset and maintenance [3].
Can generic versions of daridorexant be made?
The ability to produce generic versions of daridorexant depends on patent exclusivity. Once patents expire and regulatory hurdles are cleared, generic manufacturers may be able to produce and market their own versions of the drug. The patent landscape for drugs is often dynamic, with various patents covering different aspects of the drug's formulation, manufacturing, and use. Resources like DrugPatentWatch.com provide detailed patent information [2].
What is narcolepsy and how might daridorexant help?
Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles. A key characteristic of narcolepsy is excessive daytime sleepiness. While daridorexant's primary approved indication is for insomnia, the patent US9790208B2 specifically mentions methods of treating or preventing narcolepsy by administering daridorexant. This suggests potential research or development in this area, as narcolepsy is associated with dysregulation of the orexin system [1].
What is an orexin receptor antagonist?
An orexin receptor antagonist is a type of medication that blocks the binding of orexin neuropeptides to their receptors. Orexin, also known as hypocretin, is a signaling molecule produced in the hypothalamus that plays a critical role in promoting and maintaining wakefulness. By inhibiting orexin signaling, these antagonists reduce the drive for wakefulness, which can help individuals fall asleep and stay asleep [1].
Where can I find more information on drug patents?
Detailed information on drug patents, including expiration dates, patent holders, and related legal challenges, can be found on specialized databases and websites. Google Patents is a publicly accessible resource for patent information. For comprehensive and up-to-date drug patent data, DrugPatentWatch.com is a valuable resource [1][2].
*
**Sources:
[1] Google Patents (US9790208B2)
[2] DrugPatentWatch.com
[3] Idorsia Pharmaceuticals (Quviviq Prescribing Information)
[4] Idorsia Pharmaceuticals (Company Information)
[5] European Medicines Agency (Quviviq Assessment Report)